Organizations that enable clinical trial execution through operations, sites, recruitment, technology, and specialist services.
Psychedelic trials are unusually hard to run. Sessions last hours, sites need adapted rooms and specially trained staff, blinding is compromised by the drug’s obvious effects, and recruitment draws from populations mainstream psychiatry often fails. The organisations here supply the machinery: CROs (contract research organisations) that run trials, site networks that host them, recruitment platforms, and specialist services from rater training to session monitoring.
This category carries our deepest comparison tooling: a capability matrix mapping who does what across the trial lifecycle, and a market map showing where the infrastructure physically sits. The question map is simple: who can run, host, staff, or fill a psychedelic trial, and what evidence backs their claim to experience.
Clinical Trial Infrastructure
Psychedelic trial infrastructure spans sponsor-side CRO delivery, site capacity, recruitment, endpoint/data operations, and specialist psychedelic services.
17
CTI stakeholders
17
source-backed profiles
Full-service CROs and operational partners that can coordinate sponsor-side trial delivery across multiple lifecycle steps.
Site networks and SMOs that provide clinical locations, investigators, participant flow, and study execution capacity.
Recruitment and retention partners that help identify, screen, enroll, and keep participants engaged in studies.
Trial technology and data-operations providers for endpoint capture, eCOA/ePRO, EDC, analytics, and quality workflows.
Specialized trial-service organizations that support psychedelic-specific delivery, training, protocols, or infrastructure.
Early-phase CRO with a dedicated psychedelic clinical trials offering, set-and-setting units, controlled-substance handling, facilitator oversight, and participant recruitment infrastructure.
Full-service CRO with in-house research units in Sweden and the Netherlands. Psychedelic-specific evidence remains weaker than its general CNS and early-phase site-network capability.
U.S. site network with a dedicated psychedelics capability page, private dosing rooms, facilitator training, specialty assessment support, and participant enrollment infrastructure.
Endpoint technology and eCOA provider for CNS trials. ERT is now Clario; current source-backed evidence supports neuroscience endpoint infrastructure, while psychedelic-specific Clario claims need follow-up.
UK psychedelic and CNS trial infrastructure provider with specialist trial sites, sponsor-facing psychiatric research support, recruitment pathways, and therapist-related trial expertise.
CNS-focused CRO with public psychedelic-study recruitment and sponsor partnership evidence, including Cybin's CYB003 program and Schedule I-enabled clinical infrastructure.
Specialized psychedelic clinical trial services provider focused on therapist and facilitator training, protocol/manual support, adherence frameworks, and sponsor-facing trial preparation.
UK research-site network with psychedelic testing suites, early-phase infrastructure, controlled-drug capability, and participant recruitment for depression, PTSD, addiction, and related conditions.
New Zealand multi-site clinical research organization with early-phase facilities and partner-stated experience across multiple psychedelic studies.
Global full-service biotech CRO with explicit psychedelic collaboration evidence through its NZCR memorandum of understanding and prior psychedelic-study partnership statements.
Canadian psychedelic research-site and training infrastructure associated with Numinus and Cedar Clinical Research, with public evidence from MAPS-sponsored MDMA work and broader sponsor support.
Psychedelic clinical research consortium concept focused on SOP harmonization, site onboarding, patient registry workflows, and study-operations support, with limited external corroboration.
Trial technology and endpoint-services provider with a dedicated psychedelic research solutions page, central rating support, eCOA/ePRO workflows, and stated psychedelic-trial experience.
Australian CRO with a named role supporting Psyence BioMed's Phase IIb psilocybin-assisted psychotherapy trial, including monitoring, project management, and data handling.
UK site-network and SMO-style research provider with a dedicated psychedelic dosing room, controlled-drug capability, and recruitment pathways for depression, AUD, and neuropsychiatric trials.
Digital recruitment and prescreening platform for clinical trials. It fits recruitment infrastructure, but public psychedelic-specific sponsor or trial evidence was not found in this pass.
Global full-service CRO with a dedicated psychedelic center of excellence and stated experience supporting industry-sponsored psychedelic programs across psychiatric indications.
A small set, and the capability matrix on this page exists to answer exactly this: it maps each organisation’s claimed capabilities against the evidence we could document, from named trial involvement to public statements. Verified psychedelic trial experience remains scarcer than marketing suggests.
Dosing sessions of six to eight hours with two monitors present, controlled-substance licensing at every site, therapy components that need trained and supervised staff, and functional unblinding (participants usually know what they received, which complicates placebo controls). Sites and vendors without psychedelic experience underestimate all four.
The site networks group lists multi-site organisations, and the market map shows geography. Cross-referencing with our trials database shows which sites appear in registered psychedelic trials, which is the strongest evidence of real experience.